News

Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at hscora@ouhsc.edu so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, June 22, 2020

SoonerTrack Update:  Due to the ongoing PeopleSoft implementation, SoonerTrack will tentatively be down from

noon on Saturday the 27th to noon on Sunday the 28th.  This time is subject to change and we will keep you posted.

 

 

A Walk-Through of the PHS Human Subjects and Clinical Trials Information Form

PHS has updated their video to align with the latest form update (FORMS-F).

https://nexus.od.nih.gov/all/2020/06/02/a-walk-through-of-the-phs-human-subjects-clinical-trials-information-form/

 

 

OMB M-20-26: Extension of Administrative Relief for Recipients and Applicants of Federal Financial

Assistance (COVID-19) - a memo was published by OMB, extending certain of the flexibilities provided by M-20-17.

https://www.whitehouse.gov/wp-content/uploads/2020/06/M-20-26.pdf

 

 

NIH WILL ACCEPT PRELIMINARY DATA AS POST-SUBMISSION MATERIAL AND OTHER COVID-19 RELATED

APPLICATION FLXIBILITIES

https://nexus.od.nih.gov/all/2020/06/09/accepting-preliminary-data-as-post-submission-material-and-other-covid-19-related-application-flexibilities/

 

 

Oklahoma Covid-19 Working Group

Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the  OCTSI

Website ( http://octsi.ouhsc.edu/covid-19%20working%20group ) A list of investigators in the working group and their

planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is

also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please

contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and

Immunology, OUHSC ( mark-lang@ouhsc.edu ).

 

 

Oklahoma Shared Clinical and Translational Resources Clinical and Translational Research Pilot

(CTRP) Grants

The purpose of the program is to provide funding for collaborative and/or multi-disciplinary clinical and translational

pilot projects between investigators of the OSCTR member institutions. The program seeks to support proposals

designed to generate preliminary data that will result in improved health and/or healthcare for citizens of Oklahoma

and other IDeA states and enhance the competitiveness of the investigators for future extramural funding. The

program also seeks to fund innovative concepts, approaches, and methodologies that bring fresh new ideas to

solving the health issues of those living in Oklahoma and collaborating IDeA states. Projects that focus on the

medically underserved and on health concerns prevalent within Oklahoma and our OSCTR partners will be a priority.

Only projects which meet the NIH definition of clinical and/or translational research will be accepted.

Approved CTRP grants will be funded for a period starting January 1, 2021 contingent on NIH approval of just in

time (JIT) information. All funds are required to be expended by December 31, 2021.

The forms, instructions, and submission link can be found at:  http://osctr.ouhsc.edu/pilots2020

Deadlines for submission:   Pilot Proposal – Friday, August 7, 2020 at 5:00 PM CDT

 

 

Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory

(CERE) Awards

This program is intended to support community engagement to develop funded research partnerships. Funds can be

used for research development activities, including convening partners, working with individuals pursuing related work,

and conducting needs assessments in community settings. The funds cannot be used to support actual human-subjects

research protocols, which can be funded under other OSCTR pilot research programs and/or external funding.

The application should consist of a 2-page letter from the main applicant (which can be either a community agency or

an academic researcher) describing the collaboration, the contributions that the proposed work will make to a successful

research partnership, and a line item budget. Budget requests are expected to be $5,000-$10,000 with budgets that

permit the expenditure of the entire award by June 30, 2021. A separate letter of support from either the academic or

community partner indicating their agreement with the proposed activities should also be included. Proposals will be

evaluated on a rolling basis beginning July 1, 2020. Please submit proposals by email to osctr@ouhsc.edu.

Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting

the OSCTR staff at osctr@ouhsc.edu or call 405-271-3480.

URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/OSCTR Pilot instructions 2020.pdf?ver=2020-06-15-070451-763

URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/OSCTR CERE instructions 2020.pdf?ver=2020-06-15-070451-780

 

 

Office of Technology Commercialization presents a new opportunity to engage with industry (email otc@ou.edu

or meredith-wilkerson@ouhsc.edu for specific submission details):

Astellas Pharma is looking to engage with academia for developing novel early-stage small molecule compounds

having potential to cure disease (OUT OF SCOPE: cancer, infectious disease, metabolic disease, CNS disease, rare

diseases).  Non-confidential summary application (~template available~) due July 20th, 2020.

Required:

  • Significant in vivo efficacy that can reverse pathophysiology

Preferences:

  • Drug-like properties
  • Higher activity in target cell
  • Higher target specificity
  • Clarified direct target binding and/or modification
  • Patentability

For additional information, go to:   http://www.ou.edu/otc/ICO

 

 

OUHSC Researchers,

The OU Medicine Laboratory is looking for equipment to assist with their COVID-19 testing.  Please see the

attached list of equipment needs. Please reply to VPR@ouhsc.edu if you have any of this equipment you could possibly loan.

URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/COVID Ramp Up Ask List.docx?ver=2020-06-01-083246-413

 

DONATION OF TESTING SUPPLIES

OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the Testing

supplies listed in the attached “Testing Donations”.  Please return the complete form to Kristen.Namey@oumedicine.com

URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Testing Donations.xlsx?ver=2020-06-01-083249-427

 

DONATION OF PPE SUPPLIES

OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the PPE

supplies listed in the attached “research PPE donation”.  The first line is an example of how to fill out the form.  Please

return completed form to Erin-Bailey@ouhsc.edu.

URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Copy of research PPE donation.xlsx?ver=2020-06-01-083245-163

 

Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:  

https://research.ouhsc.edu/Resources/COVID-Research-Updates

 

 

Fast-Grants – Fast Funding for COVID-19 Science

https://fastgrants.org/

 

 

NIH has created a central site for its current COVID-19 guidance at

https://grants.nih.gov/policy/natural-disasters/corona-virus.htm

 

 

OUHSC Financial Administrators:

The federal and state governments are asking that all institutions track their expenditures related to the

COVID-19 pandemic.  It is imperative that everyone is diligent in tracking all COVID-19 related expenditures for future 

reimbursement opportunities.  Effective immediately, all COVID-19-related expenditures incurred since March 12 should be

coded to a newly created COVID subclass. These expenditures include, but are not limited to direct COVID-19 costs,

increased housekeeping and maintenance costs, expenditures related to business process modifications, preparatory actions,

daily operations, and communications resulting from COVID-19.  If COVID related expenses, since March 12, have already

been paid, please process a cost transfer using the new COVID subclass. Research faculty and staff should also track their

expenditures incurred by the shutdown of their projects and laboratories including the loss of samples, reagents, animals

and other items.   Also, keep in mind that, asyou resume your activities in your lab, any expenses required to restart the lab

should be coded with the COVID subclass.  This will help significantly when applying for any administrative supplements or

other COVID-19 related relief efforts. Questions regarding the use of the subclass on non-research chartfields should be

forwarded to judy-olson@ouhsc.edu and research related questions can be sent to tamara-franklin@ouhsc.edu.

 

 

OUHSC Funding Requests related to COVID-19 – when submitting an item in the OUHSC SoonerTrack system

related to COVID-19 please include “COVID-19” in the title so that we are able to search on it later.

 

 

COVID-19/Coronavirus Resources – a list from InfoEd

https://www.infoedglobal.com/COVID19/COVID-19.html

 

 

Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research

on Coronavirus Disease 2019 (COV-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)

https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html

 

 

Attention: OUHSC FY20 State Contract Budget Planning

F&A (IDC) are real costs incurred by the department and the University in support of sponsored activities.  The funding

derived from F&A provides critical dollars necessary to support the operating expenses related to the space in which the

project is conducted, as well as the various services provided to the Principal Investigator and the college and department

for administering the contract (e.g., accounting, purchasing, human resources). Without appropriate recovery of F&A costs,

the University loses money and we must be fiscally responsible to our tax payers and students.  It is not responsible

stewardship to waive these costs. Since this is the time of year when a lot of departments and faculty start their FY21 budget

planning for their anticipated state contracts, we wanted to remind everyone that no F&A reduction or waiver requests will be

approved this year.  As always, Please see this link for current F&A rates:

https://research.ouhsc.edu/Research-Administration/Forms-and-Rates/F-A-Rates

To review OUHSC Facilities and Administration Policy for Externally Funded Projects, please see this link:

https://www.ouhsc.edu/policy/#19931993-section-572---university-of-oklahoma-health-sciences-center-facilities-and-administrative-costs-policy-for-externally-funded-projects

 

 

NIH NOTICES

 

Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic (NOT-OD-20-123)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-123.html

 

Pre-Application Webinar for NCI's Serological Sciences Network Funding Opportunities (RFA-CA-20-038, RFA-CA-20-039)

(NOT-CA-20-074)
https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-074.html

 

Notice of Clarification to PAR-19-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)"

(NOT-DA-20-062)
https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-062.html

 

Notice of Pre-Application Webinar and Frequently Asked Questions (FAQs) for PAR-20-220 " Institutional Network Award for

Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1 - Clinical Trial Not Allowed) " (NOT-DK-20-027)
https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-027.html

 

Notice of Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences

(NOT-GM-20-036)
https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-036.html

 

Notice of Availability of National Children’s Study (NCS) Vanguard Biological and Environmental Sample Materials

(NOT-HD-20-018)
https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-018.html

 

Notice of Participation of National Institute of Nursing Research (NINR) in PA-20-135 "Emergency Competitive Revision

to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional")
(NOT-NR-20-005)
https://grants.nih.gov/grants/guide/notice-files/NOT-NR-20-005.html

 

Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision

Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency

(NOT-OD-20-118)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-118.html

 

Guidance Regarding Change in Status, Including Absence of PD/PI and Other Key Personnel Named in the Notice of Award

(NOT-OD-20-124)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-124.html

 

Notice of Pre-Application Webinars for the High-Risk, High-Reward Research Program's Pioneer, New Innovator, Transformative

Research, and Early Independence Awards (NOT-RM-20-021)
https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-021.html

 

Request for Information: Soliciting Input on the NIGMS 2021-2025 Strategic Plan Framework
(NOT-GM-20-034)
https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-034.html

 

Notice of NLM's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement –

Clinical Trial Optional)" (NOT-LM-20-012)
https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-012.html

 

Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement –

Clinical Trial Optional)" (NOT-MH-20-064)
https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-064.html

 

Notice of Extension of the Response Date for NOT-NS-20-026 "Request for Information: Soliciting Input on Areas of Health

Disparities and Inequities in Neurological Disease and/or Care in the United States Across the Lifespan" (NOT-NS-20-075)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-075.html

 

Notice of Change in Application Due Date for NOT-OD-20-107 "Notice of Special Interest (NOSI): Administrative Supplements

to Existing NIH ECHO Cooperative Agreements (Admin Supp - Clinical Trial Not Allowed) for COVID-19 related Research"

(NOT-OD-20-117)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-117.html

 

Notice of Intent to Publish a Funding Opportunity Announcement for INIA Research Project (U01 Clinical Trial Optional)

(NOT-AA-20-016)
https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-016.html

 

Notice of Special Interest (NOSI): NIAID Priorities for Biomedical Knowledgebases and Repositories
(NOT-AI-20-044)
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-044.html

 

Notice of Special Interest (NOSI): Role of Astrocytes and Astrocytic Networks in Drug Abuse
(NOT-DA-20-060)
https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-060.html

 

Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases

(Reissue) (NOT-HL-20-796)
https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-796.html

 

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications

(SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
(NOT-OD-20-119)

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-119.html

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19

Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-120)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-120.html


Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged

Research on COVID-19 Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-121)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-121.html

 

 

Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least two months prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.

 

NIH DEADLINES

 

Administrative Supplement for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed) (PA-20-227) 

Deadline October 15, 2020 and January 15, 2021 

https://grants.nih.gov/grants/guide/pa-files/PA-20-227.html

 

Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanicals and Other Natural Products

(PI2 CARBON) (R03 Clinical Trials Not Allowed) (PAR-20-228) - Deadline October 1, 2020 and June 1, 2021 

https://grants.nih.gov/grants/guide/pa-files/PAR-20-228.html

 

Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) (PAR-20-229)
Deadline August 14, 2020 and August 3, 2021 

https://grants.nih.gov/grants/guide/pa-files/PAR-20-229.html

 

Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01)

(PAR-20-230) – Deadline Continuous

https://grants.nih.gov/grants/guide/pa-files/PAR-20-230.html

 

Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)
(RFA-AG-21-024) - Deadline October 29, 2020 

https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-024.html

 

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional)
(RFA-CA-20-035) – Deadline September 4, 2020

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-035.html

 

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional)
(RFA-CA-20-036) – Deadline September 4, 2020

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-036.html

 

Collaborative Centers in Children's Environmental Health Research and Translation Centers (P2C Clinical Trial Optional)

(RFA-ES-20-001) - Deadline November 23, 2020

https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-001.html

 

Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)

(RFA-OD-20-013 - Deadline August 7, 2020 

https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-013.html

 

Print